StoneX Group’s Precision BioSciences DTIL Stock Holding History

StoneX Group’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-543	Closed	-$26.1K	–	393
2022 Q2	$26.1K	Buy	+543	New	+$31.9K	﹤0.01%	428

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

StoneX Group's DTIL Position: Q3 2022 in Review

StoneX Group sold out of Precision BioSciences (DTIL) in Q3 2022, closing a stake of 543 shares — an estimated $26.1K sold.

StoneX Group first reported a position in DTIL in Q2 2022 and held it in 1 quarter. The position peaked at $26.1K in Q2 2022. 102 funds tracked by Wall St. Rank hold DTIL as of Q3 2022.

StoneX Group reported no remaining Precision BioSciences position as of Q3 2022 after selling out during the quarter.
StoneX Group sold 543 Precision BioSciences shares in Q3 2022, an estimated $26.1K.
StoneX Group first reported a position in Precision BioSciences in Q2 2022 and held it in 1 quarter.
StoneX Group's Precision BioSciences position peaked at $26.1K in Q2 2022.
102 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2022.

Based on StoneX Group's 13F filing for Q3 2022, filed 8 Nov 2022.